Please Note:
This profile was automatically generated using 3 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 3 references found on the Internet. This information has not been verified. Learn more...
Web References
-
1. Oncology World
www.oncology-world.com/online/ - [Cached]Published on: 10/25/2002 Last Visited: 10/25/2002
Dr. Wolfgang Beier (CEO) Wolfgang Beier is the founder of Oncology World. He has more than 20 years experience in the pharmaceutical industry especially in product development, clinical research and strategic R&D management. His oncological expertise is based on decade long experience in clinical research of oncological and immunological substances. He is also the founder and chairman of PFK International, a full-service CRO focused on oncology. -
2. www.computerbusinessreview.com
www.computerbusinessreview.com - [Cached]Last Visited: 2/20/2008
Wolfgang Beier, CEO of Oncology Services Europe, said: "After a careful evaluation of the EDC market we identified Marvin as the best solution to address our two major requirements. -
3. DataEdge CRO Capability Assessment Service, CRO P List
www.dataedge.com/crop.htm - [Cached]Published on: 7/10/2001 Last Visited: 3/6/2002
The Headquarters were founded in 1992 by Dr. Wolfgang Beier, Chairman and CEO, and are located near Munich, Germany (the facility is relocating to Munich in January 2002). Here, a staff of 28 highly qualified people is employed. The clinical team is composed of medical doctors with relevant clinical background, scientists with relevant basic science background and oncology nurses, knowing how to deal with all monitoring and site related aspects.
Kaufbeuren is the coordinating central office for the network-partners in UK, France, Italy, Spain and Eastern Europe. In Germany PFK International has established an intensive co-operation with the German Cancer Society (Deutsche Krebsgesellschaft), being an official member of the DKG as well as a co-operation partner of the DKG in the study house of oncology (Studienhaus Onklogie). This enables the access to highly experienced and qualified sites with fast and sufficient patient recruitment.
